Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 5/20 | 0.78 |
| ▸ | GSK3B | P49841 | 10/20 | 0.74 |
| ▸ | GSK3A | P49840 | 9/20 | 0.74 |
| ▸ | CDK2 | P24941 | 4/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623633 | 1.00 | PIK3CG (0.78) | PIK3CGGSK3BGSK3ACDK2PIK3CA | |
| SCHEMBL622799 | 0.86 | PIK3CG (0.80) | PIK3CGGSK3BGSK3APIK3CAPIK3CB | |
| SCHEMBL622801 | 0.86 | PIK3CG (0.80) | PIK3CGGSK3BGSK3APIK3CAPIK3CB | |
| SCHEMBL622800 | 0.86 | PIK3CG (0.80) | PIK3CGGSK3BGSK3APIK3CAPIK3CB | |
| SCHEMBL623772 | 0.85 | GSK3B (1.00) | PIK3CGGSK3BGSK3ACDK2PIK3CA | |
| SCHEMBL623771 | 0.85 | GSK3B (1.00) | PIK3CGGSK3BGSK3ACDK2PIK3CA | |
| SCHEMBL10118549 | 0.85 | GSK3B (0.70) | PIK3CGGSK3BGSK3ACDK2PIK3CA | |
| SCHEMBL15313049 | 0.85 | GSK3B (0.70) | PIK3CGGSK3BGSK3ACDK2PIK3CA | |
| SCHEMBL622538 | 0.82 | PIK3CG (0.79) | PIK3CGGSK3BGSK3ACDK2PIK3CA | |
| SCHEMBL622537 | 0.82 | PIK3CG (0.79) | PIK3CGGSK3BGSK3ACDK2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | PIK3CG 3728/4885GSK3B 4721/4885GSK3A 4773/4885 |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | PIK3CG 3728/4885GSK3B 4721/4885GSK3A 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.